Breaking News

Euprotec, Cantab Enter Antibiotics Development Pact

May 7, 2014

Aims to improve treatments for multi-drug resistant bacterial infections

Euprotec, Ltd. has entered an alliance with Cantab Anti-infectives to develop improved antibiotics to treat multidrug resistant Gram-negative bacterial infections.The program will focus on developing improved therapeutics based on polymyxin, a class of antibiotics with a unique and important target and are currently viewed as a last resort when treating severe infections due to multidrug resistant Gram negative bacteria.
Euprotec will provide microbiology services to help facilitate the identification and optimization of a new drug candidate using its biology platform and highly characterized collection of bacteria to optimize the potency and efficacy of new compounds. The approach will allow profiling of PKPD parameters for translation of preclinical data to clinical trials.
Dr. Lloyd Payne, chief executive of Euprotec, said, “We are thrilled that Cantab has selected Euprotec as its infectious disease biology partner for this programme.  Multidrug resistant Gram negative bacterial infections pose an enormous threat, and we look forward to working with Cantab to realise the exciting potential of their antibiotic platform.”
Dr. Mike Dawson, chief executive of Cantab, said, “We selected Euprotec as our primary biology partner for this programme due to its strong reputation for delivery in the infectious disease therapeutic area as well as the depth and breadth of their portfolio and expertise. The specialist knowledge and technical skills that Euprotec provides will supplement our in-house research team perfectly and we are looking forward to working with them as we progress our discovery and development program.”

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems